الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 190 |  |  |
| | | from | 190 | | |
Abstract
Cardiometabolic syndrome is one of the major public health issues of this century which describes a cluster of clinical characteristics whose components vary considerably among different individuals and different racial and ethnic groups.
The pathogenesis of the metabolic syndrome is multifactorial, but insulin resistance, obesity and sedentary lifestyle, DNA damage, and genetic factors interact in its occurrence leading to type 2 diabetes, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.
There is wide variation in both the occurrence of disease and age of onset, even in individuals who display similar risk profiles. Interplay between genetic determinants and environmental factors (still largely unknown) are the reason for this large inter-individual variation in disease susceptibility.
First-line therapy should be weight reduction reinforced with increased physical activity. Weight loss lowers serum cholesterol and triglycerides, raises HDL cholesterol, lowers blood pressure and glucose, and reduces insulin resistance.
Exercise, especially when associated with weight loss, improves all of the components of the metabolic syndrome.
Drug therapy is also used to target individual risk factors for cardiometabolic syndrome. Drug therapy includes lipid-lowering drugs, antihypertensive agents, hypoglycemic drugs, antiplatelet drugs, and weight loss agents. It is recommended that the use of these drugs follow current treatment guidelines.